IGSC 20% Biweekly Dosing in PI

Phase 4, open-label trial of immune globulin subcutaneous, human-klhw in primary immunodeficiency (PI) (2 arms), sponsored by Grifols. Primary endpoints: Steady-State Area Under the Curve (AUC) of Total IgG Over a Regular Dosing Interval (tau) - Weekly Administration at Week 15 and Steady-State Area Under the Curve (AUC) of Total IgG Over a Biweekly Dosing Interval - Biweekly Administration at Week 32. Started Nov 2020; status: completed.